LUCID DIAGNOSTICS INC.
Lucid Diagnostics (NASDAQ: LUCD) is a commercial-stage diagnostics company that sells the EsoGuard NGS-based DNA methylation test and EsoCheck non-invasive cell collection device for detecting esophageal precancer in at-risk GERD patients, distributing through physician referrals, the VA, the WTC Health Program, employer programs, and concierge medicine.
- Company typePublic
- Founded2018
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What LUCID DIAGNOSTICS INC. does
Lucid Diagnostics Inc. (NASDAQ: LUCD), founded in 2018 and headquartered in New York with a CLIA-certified, CAP-accredited clinical laboratory in Lake Forest, California, is a commercial-stage cancer prevention diagnostics company and majority-owned subsidiary of PAVmed Inc. The company develops and sells EsoGuard, a Next Generation Sequencing-based DNA methylation assay that quantifies methylation at 31 sites on two genes (Vimentin and CCNA1), paired with EsoCheck, an FDA 510(k)-cleared and CE-Marked non-invasive swallowable balloon capsule catheter that collects surface esophageal cells in an office procedure of under three minutes. Together the system is positioned as a non-invasive alternative to endoscopy for detecting esophageal precancer (Barrett's Esophagus) in at-risk patients, primarily those with GERD, and has received FDA Breakthrough Device designation with two ongoing international multicenter trials supporting an FDA PMA submission.
The company monetizes EsoGuard on a per-test basis, billing medical insurance carriers including Medicare, the VA at established Medicare rates (~$2,000 per test), and commercial payers, with a financial assistance program for underinsured patients. Its go-to-market combines a direct sales force driving primary care physician referrals to a network of Lucid Test Centers with major institutional channel partners: the U.S. Department of Veterans Affairs Federal Supply Schedule (covering ~9 million enrolled veterans across ~170 medical centers), the World Trade Center Health Program (120,000+ covered 9/11 responders), concierge medicine contracts such as LEAA Health, employer-sponsored screening programs, and community outreach via the #CheckYourFoodTube firefighter testing events (4,000+ firefighters screened across 105+ events).
Revenue is at an early commercial scale with Q1 2026 test revenue of $1.3M on 3,177 tests and quarterly volumes fluctuating between approximately 2,800 and 3,700 tests through 2025-2026. Lucid has raised substantial equity capital, including a $70M IPO in October 2021, a $29.8M Series B/B-1 in May 2024, and multiple underwritten public offerings through April-May 2026, ending Q1 2026 with $45M in pro forma cash and a stated runway into 2027. The company's near-term commercial trajectory is closely tied to securing broad Medicare coverage via CMS MolDX and converting its anchor institutional contracts into sustained test volume.
LUCID DIAGNOSTICS INC. firmographics
Firmographics- Name
- LUCID DIAGNOSTICS INC.
- Legal name
- Lucid Diagnostics Inc.
- Website
- https://luciddx.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Lucid Diagnostics (NASDAQ: LUCD) is a commercial-stage diagnostics company that sells the EsoGuard NGS-based DNA methylation test and EsoCheck non-invasive cell collection device for detecting esophageal precancer in at-risk GERD patients, distributing through physician referrals, the VA, the WTC Health Program, employer programs, and concierge medicine.
- Ownership category
- akta.pro rank
LUCID DIAGNOSTICS INC. industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
- akta.pro secondary industry
- Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)
Keywords
Where LUCID DIAGNOSTICS INC. is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
LUCID DIAGNOSTICS INC. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- EsoGuard Diagnostic Testing: Revenue generated from processing EsoGuard Esophageal DNA tests. Tests are billed to insurance carriers including Medicare, VA, and commercial payers. Q1 2026 recognized $1.3 million in revenue with 3,177 tests processed.
- Government Contracts: Contract with U.S. Department of Veterans Affairs under Federal Supply Schedule at Medicare payment rates (~ $2,000 per test). Access to VA healthcare system serving 9 million enrolled veterans.
- Patient Financial Assistance: Financial Assistance Program for qualified patients who cannot afford out-of-pocket costs after insurance. Multiple payment plans available for non-qualified patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | VA Federal Supply Schedule pricing |
| Unit Pricing | Pay-as-you-go | Medicare payment rates |
| Other | Pay-as-you-go | Insurance billing with financial assistance |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels6 records
LUCID DIAGNOSTICS INC. product offering
Product offeringCore offering
Lucid Diagnostics develops and commercializes the EsoGuard Esophageal DNA Test, a Next Generation Sequencing (NGS)-based DNA methylation assay that quantifies methylation at 31 sites on two genes (Vimentin and Cyclin A1) to detect esophageal precancer (Barrett's Esophagus). Samples are collected using the EsoCheck device, a CE Marked and FDA 510(k) cleared swallowable balloon capsule catheter that enables a non-invasive, office-based cell collection procedure in under three minutes. Tests are processed at the company's CLIA-certified, CAP-accredited LucidDx Labs facility in Lake Forest, California.
Product overview
Lucid Diagnostics offers two core commercial products for esophageal precancer and cancer detection: the EsoGuard® Esophageal DNA Test and the EsoCheck® Esophageal Cell Collection Device. These products work together as an integrated system—the EsoCheck device collects surface esophageal cells during a brief, non-invasive office procedure, and the EsoGuard test analyzes these samples using Next Generation Sequencing-based DNA methylation technology to detect esophageal precancer (Barrett's Esophagus) before it progresses to cancer. The company is focused on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer.
Differentiator
Problem solved
Functional benefit
Brands
- EsoGuard: EsoGuard Esophageal DNA Test - A Next Generation Sequencing based DNA methylation assay performed on surface esophageal cells collected with EsoCheck, quantifying methylation at 31 sites on two genes (Vimentin and Cyclin A1) for detection of esophageal precancer and cancer.
- EsoCheck
Products and services
- EsoGuard Esophageal DNA Test A Next Generation Sequencing (NGS) based DNA methylation assay performed on surface esophageal cells collected with EsoCheck, quantifying methylation at 31 sites on two genes (Vimentin and Cyclin A1) to detect esophageal precancer (Barrett's Esophagus) and esophageal cancer. It received FDA Breakthrough Device designation and is the subject of large international multicenter clinical trials for FDA PMA approval. The test is intended for use by clinicians managing at-risk GERD patients.
- EsoCheck Esophageal Cell Collection Device A CE Marked and FDA 510(k) cleared noninvasive swallowable balloon capsule catheter device that samples surface esophageal cells in a less than three-minute office procedure. It is used in conjunction with the EsoGuard Esophageal DNA Test for esophageal precancer detection, targeting at-risk GERD patients managed by primary care physicians and gastroenterologists.
Quantifiable outcome
- 87.5-92.9% sensitivity for Barrett's Esophagus detection
- +4 more outcomes
Companies that use LUCID DIAGNOSTICS INC.
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles5 records
LUCID DIAGNOSTICS INC. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
LUCID DIAGNOSTICS INC. partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered flagship, minor and core.
- U.S. Department of Veterans AffairsflagshipVA Federal Supply Schedule contract for EsoGuard esophageal precancer testing. Pricing matches Medicare rates (~$2,000/test). Access to VA healthcare system serving 9 million enrolled veterans across ~170 VA medical centers.
- LEAA HealthminorFirst concierge medicine contract - LEAA Health membership-based concierge patients access EsoGuard testing as part of enhanced personalized care service on cash-pay basis.
- Mass General BrighamcorePhysician partnership facilitating #CheckYourFoodTube esophageal precancer testing events. Mass General Brigham physicians Kumar Krishnan, M.D. and Alexandra Maltby organized events with Boston Firefighters Local 718 IAFF.
- Boston Firefighters Local 718 IAFFcorePartnership with International Association of Fire Fighters Local 718 for #CheckYourFoodTube precancer testing events. Firefighters have 62% increased risk of esophageal cancer. 4,000th firefighter milestone achieved.
- World Trade Center Health ProgramcoreContract providing EsoGuard esophageal precancer testing as covered benefit for 120,000+ World Trade Center Health Program participants (9/11 responders and survivors).
- UpScriptHealthcoreTelemedicine partnership for EsoGuard testing program. UpScript provides physician evaluation and referral services for rapid, office-based EsoGuard testing. Initially launched in Phoenix, Denver, Salt Lake City, and Las Vegas markets.
- National Cancer Institute (NCI)coreNCI-funded BETRNet consortium study validating EsoGuard performance. Study published in American Journal of Gastroenterology. Represents third major NCI-funded validation study.
- American College of Gastroenterology (ACG)coreACG guidelines recommend non-endoscopic biomarker testing such as EsoGuard as acceptable alternative to endoscopy for esophageal precancer screening. ACG guideline lead author involved in clinical studies.
- Nicholas J. Shaheen, M.D., M.P.H.coreLead investigator of ESOGUARD BE-1 clinical validation study. Bozymski-Heizer Distinguished Professor of Medicine and Epidemiology at UNC School of Medicine. Lead author of ACG guidelines on esophageal precancer screening.
Scale indicators14 records
Recent moves8 records
Expansion highlights6 records
LUCID DIAGNOSTICS INC. competitors and assessment
Company assessmentDirect peers
- Exact Sciences Corp: Developer of Cologuard, the leading non-invasive stool DNA methylation-based colorectal cancer screening test. Closest direct comparable to Lucid: same FDA pathway (Breakthrough → PMA), same commercial motion targeting primary care, similar reimbursement and adoption dynamics, and same technology class (methylation-based biomarker screening).
- Interpace Diagnostics: Molecular diagnostics company offering esophageal and pancreatic cancer molecular diagnostic tests (e.g., Eso-Prep, BarreGEN). Direct indication overlap with EsoGuard in esophageal precancer detection, with similar specialty-lab business model and PCP/GI referral channels.
Broad incumbents
- Guardant Health: Liquid biopsy cancer detection company with FDA-approved Shield colorectal cancer screening test. Targets similar end customers (PCPs, gastroenterologists) and operates in the non-invasive cancer screening space, though with broader oncology franchise and liquid biopsy technology rather than methylation cell-based assay.
- Natera: Cell-free DNA testing company with Signatera MRD test and broader reproductive and oncology testing portfolio. Comparable as an oncology-focused diagnostics company selling to clinicians with similar reimbursement and clinical evidence requirements, though not a direct cancer-screening competitor.
- Medtronic (Cytosponge): Global medical device incumbent that has commercialized Cytosponge, a non-endoscopic sponge-on-a-string esophageal cell collection device for Barrett's screening. Most directly comparable product/technology in esophageal precancer detection, though Medtronic operates across many franchises and does not focus exclusively on this niche.
- NeoGenomics: Oncology-focused clinical laboratory services company offering molecular and genetic testing. Adjacent comparable as a CLIA-certified cancer diagnostics laboratory serving oncologists, though broader in scope and lacking a single flagship screening product equivalent to EsoGuard.
Emerging players
- GRAIL: Subsidiary of Illumina commercializing Galleri, a multi-cancer early detection blood test. Competes for the same non-invasive cancer screening budget and patient awareness, with overlapping PCP-facing commercial model and similar regulatory and reimbursement challenges.
- Mainz Biomed: Molecular diagnostics company developing ColoAlert, a stool-based DNA colorectal cancer screening test. Closely analogous to Lucid in stage (pre-commercial/scale-up), technology class (DNA-based biomarker screening), and commercial/reimbursement hurdles, making it a strong comparable.
- VolitionRx: Blood-based cancer diagnostics company with Nu.Q nucleosome-based biomarker platform. Comparable in being an early-stage cancer diagnostic company pursuing non-invasive blood-based biomarker detection with similar regulatory and reimbursement pathways.
Others
- Fulgent Genetics: Genetic testing services company offering molecular and hereditary cancer testing. Operates a similar CLIA-based molecular diagnostics platform and sells to clinicians and healthcare systems, though positioned in hereditary cancer and broader genetic testing rather than non-invasive screening.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
LUCID DIAGNOSTICS INC. social profiles
Digital presenceLUCID DIAGNOSTICS INC. financial estimates
Financial estimateRevenue estimate
Valuation estimate
LUCID DIAGNOSTICS INC. leadership team
Management profileNumber of profiles
Profiles8 records
LUCID DIAGNOSTICS INC. funding detail
Funding detailFunding overview
Funding rounds8 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LUCID DIAGNOSTICS INC. M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LUCID DIAGNOSTICS INC.
What does LUCID DIAGNOSTICS INC. do?
Lucid Diagnostics develops and commercializes the EsoGuard Esophageal DNA Test, a Next Generation Sequencing (NGS)-based DNA methylation assay that quantifies methylation at 31 sites on two genes (Vimentin and Cyclin A1) to detect esophageal precancer (Barrett's Esophagus). Samples are collected using the EsoCheck device, a CE Marked and FDA 510(k) cleared swallowable balloon capsule catheter that enables a non-invasive, office-based cell collection procedure in under three minutes. Tests are processed at the company's CLIA-certified, CAP-accredited LucidDx Labs facility in Lake Forest, California.
Is LUCID DIAGNOSTICS INC. a public or private company?
LUCID DIAGNOSTICS INC. is a public company. It is classified as public and is currently operating.
When was LUCID DIAGNOSTICS INC. founded?
LUCID DIAGNOSTICS INC. was founded in 2018. It employs 101 to 250 people.
Where is LUCID DIAGNOSTICS INC. based?
LUCID DIAGNOSTICS INC. is headquartered in New York, United States, in the North America region.
How does LUCID DIAGNOSTICS INC. make money?
Three revenue lines are on record. EsoGuard Diagnostic Testing is the primary driver. The others are government Contracts and patient Financial Assistance.
Who are LUCID DIAGNOSTICS INC.'s main competitors?
Direct peers on record are Exact Sciences Corp and Interpace Diagnostics. Broad incumbents are Guardant Health, Natera, Medtronic (Cytosponge) and NeoGenomics. Emerging players are GRAIL, Mainz Biomed and VolitionRx. Fulgent Genetics is listed as an others.
Does LUCID DIAGNOSTICS INC. have an API?
No public API is recorded for LUCID DIAGNOSTICS INC..
What industry is LUCID DIAGNOSTICS INC. in?
LUCID DIAGNOSTICS INC.'s product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD, with a secondary code of HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation). Its NAICS code is 325413 and its SIC code is 2835.